PRESS-RELEASE filed May 7, 2026 at 16:01 ET
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting widening losses as the company invests heavily in its pipeline. Positively, the company completed enrollment six months ahead of schedule in its Phase 3 barzolvolimab CSU studies, with topline data expected in Q4 2026 and a BLA submission planned for 2027, and strengthened its balance sheet with a $345M public offering in April. The mixed report balances near-term financial deterioration against significant pipeline progress and a cash runway through 2028.